The Leapfrog Group is out with its biannual report card on hospitals' safety and qualify efforts, and it's clear that ...

April may not have brought rain to med-tech, but tariffs and financial uncertainty certainly dampened the enthusiasm for IPOs. With those clouds lifting, three companies – Hinge Health Inc., ...

April data and first quarter earnings reports show remarkable resilience in med tech, even as other sectors continue to suffer in response to tariffs and changing regulations. Not that tariffs proved ...

Smart prescription bottle technology offers parents and caregivers enhanced oversight, ensuring child safety and medication ...

Sequel Med Tech and Senseonics today announced a commercial development agreement to combine insulin delivery and glucose ...

Because acetaminophen is often prescribed to mothers who are experiencing pain after giving birth, it's inevitable that some of the medication will make its way through to the infant in the breast ...

Guilford Street Laboratories, a university spin-out focused on the child health sector, has completed a follow on investment round. The venture is a spin-out of University College London and in ...

With three decades of spearheading advances in precision medicine and diagnostic technologies, King will accelerate the company's next phase of expansion. CHICAGO, April 15, 2025--(BUSINESS WIRE ...

Thank you for signing up! Did you know with a Digital subscription to Yorkshire Post, you can get access to all of our premium content, as well as benefiting from fewer ads, loyalty rewards and ...

April 29, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, and Senseonics Holdings, Inc. (NYSE American: SENS), a medical ...

In a classic example of scientific problem solving, scientists from the Hackensack Meridian Center for Discovery and ...

They make a lot of different parts, you go to their catalogue for med devices. I know that Starboard had a stake. . .maybe you could get a hold of them . . .but this is a terrible, terrible quarter.